StockData
Carlsmed, Inc. logo

Carlsmed, Inc. (CARL) stock

CARLNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30118% above fair value
$17.74+0.39 (+2.25%)

Close on Nov 17, 2026Market cap $484.35MP/E –Yield –

Carlsmed r&d expenses

Research and development expenses are spending on new products and technology.

Carlsmed's R&D Expenses for the twelve months ending Jun 30, 2026 was $20.93M, up 45.7% year over year. For fiscal 2025 it was $17.02M, up 19.0% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$17.02M+19.0%
FY2024Dec 31, 2024$14.30M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$6.04M+45.2%
Q1 FY2026Mar 31, 2026$5.18M+64.4%
Q4 FY2025Dec 31, 2025$5.26M+74.6%
Q3 FY2025Sep 30, 2025$4.45M+10.2%
Q2 FY2025Jun 30, 2025$4.16M+4.1%
Q1 FY2025Mar 31, 2025$3.15M–
Q4 FY2024Dec 31, 2024$3.02M–
Q3 FY2024Sep 30, 2024$4.04M–
Q2 FY2024Jun 30, 2024$4.00M–

More Carlsmed figures

See a number that looks wrong?